AREVA PHARMA
Live / Applied — First extension granted (statement of use) (as of 14 Oct 2025)
What this means for you
Not registered yet, but its 25 Mar 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98466090
- Mark type
- Stylized text
- Filed
- 25 Mar 2024
- Published for opposition
- 24 Dec 2024
- Attorney of record
- Michael S. Hargis
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of cancer, heart failure, heart disease, and hypertension; pharmaceutical preparations for use in gene therapy; pharmaceutical preparations for the treatment of cancer, heart failure, heart disease, and hypertension, in the form of oncology injectables and oral solids
Owner
- Areva Pharmaceuticals Inc., Georgetown, IN, US
- Areva Pharmaceuticals Inc., Georgetown, IN, US
Prosecution history
- 15 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Oct 2025 — SOU EXTENSION 1 GRANTED
- 14 Oct 2025 — SOU EXTENSION 1 FILED
- 14 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 05 May 2025 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 05 May 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 05 May 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 05 May 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 05 May 2025 — POST PUBLICATION AMENDMENT – NOT ENTERED
- 28 Apr 2025 — ASSIGNED TO PETITION STAFF
- 22 Apr 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 20 Mar 2025 — TEAS POST PUBLICATION AMENDMENT RECEIVED
- 12 Mar 2025 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 11 Mar 2025 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 23 Jan 2025 — EXTENSION OF TIME TO OPPOSE RECEIVED